Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

10.2K views

Cited by 6

07:43 min

September 25th, 2018

10.3791/58082-v

September 25th, 2018

10.2K views

To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.

Explore More Videos

PD L1 Immunohistochemistry

Chapters in this video

0:04

Title

1:13

Preparation of Tumor Tissue Samples

1:53

Preparation of Cytology Samples

2:56

PD-L1 Staining Assay

4:27

Interpretation of the PD-L1 Staining

5:08

Results: Analysis of the PD-L1 Staining

6:23

Conclusion

Related Videos